Floatz logo

Glargine

Type 2 Diabetes Mellitus

Cairo UniversityUNKNOWNPhase 4 / ApprovedDormant
B
59/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
73/ 100

Competitive context

135 Active assets in the Type 2 Diabetes Mellitus cohort.

Asset / SponsorPhaseRating
Liraglutide
RenJi Hospital
Phase 4BBB
Cotadutide
AstraZeneca
Phase 2BBB
Exenatide
Vivani Medical, Inc
Phase 4BBB
Dapagliflozin
Bhavya Bhavya, MD
Phase 4BBB
Semaglutide
Shanghai Jiao Tong University School of Medicine
Phase 4BBB

View all 49 →

Same molecule, other indications

Glargine is also rated in:

glucose metabolism diseaseDormant
BB
Indicative · Phase 4
69 / 100
View asset →
cystic fibrosisDormant
B
Indicative · Phase 4
62 / 100
View asset →
cirrhosis of liverDormant
B
Indicative · Phase 4
59 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →